Jasper Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 13.21 million compared to USD 9.06 million a year ago. Basic loss per share from continuing operations was USD 3.6 compared to USD 2.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.52 USD | -3.50% | -5.55% | +210.77% |
31/05 | Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 | CI |
20/05 | Transcript : Jasper Therapeutics, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+210.77% | 370M | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
+11.88% | 216B | |
-0.78% | 219B | |
+5.90% | 164B |
- Stock Market
- Equities
- JSPR Stock
- News Jasper Therapeutics, Inc.
- Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022